Доступ предоставлен для: Guest
Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции
Critical Reviews™ in Immunology
Импакт фактор: 1.352 5-летний Импакт фактор: 3.347 SJR: 0.657 SNIP: 0.55 CiteScore™: 2.19

ISSN Печать: 1040-8401
ISSN Онлайн: 2162-6472

Выпуски:
Том 39, 2019 Том 38, 2018 Том 37, 2017 Том 36, 2016 Том 35, 2015 Том 34, 2014 Том 33, 2013 Том 32, 2012 Том 31, 2011 Том 30, 2010 Том 29, 2009 Том 28, 2008 Том 27, 2007 Том 26, 2006 Том 25, 2005 Том 24, 2004 Том 23, 2003 Том 22, 2002 Том 21, 2001 Том 20, 2000 Том 19, 1999 Том 18, 1998 Том 17, 1997 Том 16, 1996 Том 15, 1995 Том 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v27.i5.20
pages 415-436

Targeting OX40 and OX40L for the Treatment of Autoimmunity and Cancer

William L. Redmond
Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Portland Medical Center, 4805 NE Glisan St., No. 5F37, Portland, OR 97213, USA
Andrew D. Weinberg
Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Portland Medical Center, 4805 NE Glisan St., No. 5F37, Portland, OR 97213, USA

Краткое описание

The optimal activation of naïve T cells requires TCR−mediated recognition of cognate peptide−MHC complexes on antigen presenting cells in the presence of costimulatory signals. Although signals provided via CD28−B7 interactions are important for enhancing the initial T−cell response, other costimulatory signals are required for sustaining the response and promoting both T−cell differentiation and survival. In particular, engagement of OX40 (CD134) by its natural ligand OX40L (CD134L) or OX40 agonists has been shown to provide key signals that can augment CD4 and CD8 T−cell responses. Importantly, numerous studies have highlighted the ability of OX40−specific agonists or antagonists to enhance antitumor immunity or ameliorate autoimmune disease, respectively. On the basis of these studies, the development of OX40− and OX40L−specific reagents has been pursued for clinical use. Given the emerging role of OX40 and OX40L as novel therapeutic targets, this review will focus on the cellular and molecular mechanisms of OX40−mediated T−cell costimulation with a special emphasis on the role of OX40-OX40L interactions in the etiology and treatment of autoimmunity and cancer.


Articles with similar content:

PART V. Modulation of Antitumor Vaccine Strategies
Preclinical and Clinical Studies of Recombinant Poxvirus Vaccines for Carcinoma Therapy

Critical Reviews™ in Immunology, Vol.27, 2007, issue 5
Philip M. Arlen, Jeffrey Schlom, Ravi A. Madan, James L. Gulley, James W. Hodge
The Role of OX40-Mediated Co-stimulation in T-Cell Activation and Survival
Critical Reviews™ in Immunology, Vol.29, 2009, issue 3
Carl E. Ruby, Andrew D. Weinberg, William L. Redmond
Dendritic Cell-Based Vaccines: From Mouse Models to Clinical Cancer Immunotherapy
Critical Reviews™ in Oncogenesis, Vol.11, 2000, issue 1
Carl G. Figdor, Gosse J. Adema, Marco W. J. Schreurs, Andreas A. O. Eggert, Cornells J. A. Punt
Immune Function of Thyroid Stimulating Hormone and Receptor
Critical Reviews™ in Immunology, Vol.21, 2001, issue 4
Heuy-Ching Wang, John R. Klein
Costimulation Signals for Memory CD8+ T Cells During Viral Infections
Critical Reviews™ in Immunology, Vol.29, 2009, issue 6
Peter D. Katsikis, Alina C. Boesteanu, Priyanka A. Duttagupta